Why the study?
Does activation of PPAR-alpha inhibit ET-1-induced cardiac hypertrophy in cardiomyocytes?
Does activation of PPAR-alpha inhibit ET-1-induced cardiac hypertrophy in cardiomyocytes?
Activation of PPAR-alpha inhibits ET-1-induced cardiac hypertrophy by regulating PI3K/Akt/GSK3beta and NFAT signaling pathways.
Extends PPAR-alpha mechanistic insights in hypertrophy models; hypothesis-generating and should not yet change practice.
Activation of peroxisome proliferator-activated receptor-alpha (PPAR-alpha) has been recently reported to inhibit vascular inflammatory response and prevent cardiac hypertrophy. However, it is unclear how the activation of PPAR-alpha regulates hypertrophic response. In the present study, we found that application of fenofibrate and overexpression of PPAR-alpha inhibited endothelin-1 (ET-1)-induced phosphorylation of protein kinase B (Akt) at Ser473 and glycogen synthase kinase3beta (GSK3beta) at Ser9, and prevented ET-1-induced nuclear translocation of NFATc4 in cardiomyocytes. Moreover, co-immunoprecipitation studies showed that fenofibrate strongly induced the association of nuclear factor of activated T cells (NFATc4) with PPAR-alpha. These results suggest that activation of PPAR-alpha inhibits ET-1-induced cardiac hypertrophy through regulating PI3K/Akt/GSK3beta and NFAT signaling pathways.
No takes yet. Share an insight, caveat, or question.
Li et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: